Article Text

THU0106 Lysophosphatidic Acid Receptor LPA1 is Essential for Development of Arthritis
  1. Y. Miyabe1,
  2. C. Miyabe1,2,
  3. Y. Iwai3,
  4. A. Takayasu1,
  5. S. Fukuda1,
  6. W. Yokoyama1,
  7. J. Nagai4,
  8. M. Jona5,
  9. Y. Tokuhara5,
  10. R. Ohkawa5,
  11. H. M. Albers6,
  12. H. Ovaa6,
  13. J. Aoki7,
  14. J. Chun8,
  15. Y. Yatomi5,
  16. H. Ueda4,
  17. M. Miyasaka9,
  18. N. Miyasaka1,
  19. T. Nanki1
  1. 1Department of Medicine and Rheumatology, Tokyo Medical and Dental University
  2. 2Department of Dermatology, Tokyo Medical University
  3. 3Molecular Immunology, Tokyo Medical and Dental University, Tokyo
  4. 4Division of Molecular and Pharmacology, Nagasaki University, Nagasaki
  5. 5Department of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan
  6. 6Laboratory of Chemical Biology, Netherlands Cancer Institute, Amsterdam, Netherlands
  7. 7Laboratory of Molecular and Cellular Biochemistry, Tohoku University, Sendai, Japan
  8. 8Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States
  9. 9Laboratory of Immunodynamics, Osaka University, Osaka, Japan


Background Lysophosphatidic acid (LPA) is a bioactive lipid that binds to a group of cell surface G protein-coupled receptors (LPA1-6) and has been implicated as an important mediator of angiogenesis, inflammation and cancer growth [1-3].

Objectives To explore the pathogenic roles of LPA1 on rheumatoid arthritis, we examined the effects of LPA1 on immune function and development of arthritis.

Methods Expression of LPA receptors on the synovial tissue was analyzed by immunohistochemistry and quantitative RT-PCR. Effect of abrogation of LPA1 on collagen-induced arthritis (CIA) was evaluated using LPA1-deficient mice or LPA1 antagonist. Fluorescence labeled-CD11b+ splenocytes were transferred into CIA mice. Twenty-four hours after the transfer, the numbers of labeled cells in the synovium were counted under fluorescent microscopy. CD4+ naïve T cells were incubated with T helper (Th)1-, Th2-, or Th17-polarizing conditions and Th differentiation was analyzed. Osteoclast formation from bone marrow cells was examined.

Results LPA1 was highly expressed in the synovium of rheumatoid arthritis (RA) compared to osteoarthritis. LPA1-deficient mice failed to develop arthritis following collagen type-II (CII) immunization. LPA1 antagonist ameliorated murine CIA. Abrogation of LPA1 was associated with reduced cell infiltrates, bone destruction in the joints, and IL-17 production from CII-stimulated splenocytes. Infiltration of transferred LPA1-deficient CD11b+ macrophages into the synovium was suppressed compared with wild-type macrophages. LPA1 antagonist inhibited the infiltration of wild-type macrophages. Differentiation into Th17, but not Th1 or Th2, and osteoclast formation were also suppressed in LPA1-deficienct mice or LPA1 inhibition in vitro.

Conclusions LPA-LPA1 signaling critically contributes to the development of arthritis by cellular infiltration, Th17 differentiation and osteoclastogenesis, suggesting that LPA1 is a promising target molecule for RA therapy.


  1. Schleicher SM, et al. PLoS One. 2011; 6: e22182.

  2. Xu X, et al. Cancer. 2010; 116: 1739-1750.

  3. Houben AJ, et al. Cancer Metastasis Rev. 2011; 30: 557-565.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.